Table 2.
Effect of different treatment regimens* on FEV1† of patients with COPD during study period
| Treatment groups* | Mean (SD) FEV1† | Mean difference (95% CI) | P value | |
|---|---|---|---|---|
| First recording | Last recording | |||
| ICS (n=204) | 1.64 (0.61) | 1.63 (0.62) | −0.01 (−0.04 to 0.03) | 0.658 |
| ICS+BB (n=43) | 1.55 (0.57) | 1.58 (0.55) | 0.03 (−0.05 to 0.10) | 0.459 |
| ICS+LABA (n=459) | 1.52 (0.60) | 1.54 (0.62) | 0.02 (−0.01 to 0.05) | 0.123 |
| ICS+LABA+BB (n=89) | 1.55 (0.54) | 1.57 (0.55) | 0.03 (−0.03 to 0.08) | 0.355 |
| ICS+LABA+Tio (n=753) | 1.22 (0.51) | 1.19 (0.51) | −0.03 (−0.06 to −0.01) | <0.001 |
| ICS+LABA+Tio+BB (n=88) | 1.27 (0.50) | 1.28 (0.53) | 0.01 (−0.06 to 0.08) | 0.749 |
| LABA or Tio (no ICS) (n=197) | 1.48 (0.58) | 1.44 (0.57) | −0.04 (−0.08 to −0.01) | 0.016 |
| BB (no ICS) (n=276) | 1.83 (0.53) | 1.74 (0.55) | −0.09 (−0.11 to −0.06) | <0.001 |
| ICS+Tio (n=81) | 1.37 (0.53) | 1.40 (0.49) | 0.03 (−0.03 to 0.09) | 0.257 |
| (LABA or Tio)+BB (n=47) | 1.67 (0.56) | 1.65 (0.57) | −0.02 (−0.09 to 0.04) | 0.435 |
| Control‡ (n=475) | 1.76 (0.62) | 1.69 (0.59) | −0.07 (−0.09 to −0.05) | <0.001 |
*Treatments: ICS=inhaled corticosteroid, BB=β blocker, LABA=long acting β agonist, Tio=tiotropium.
†FEV1=forced expiratory volume in one second (litres).
‡Control=treatment only with short acting β agonists with or without short acting antimuscarinic agent.